MicroRNA-192 suppresses liver metastasis of colon cancer

Oncogene

Volumn 33, Issue 46, 2014, Pages 5332-5340

  Geng, L ^a   Chaudhuri, A ^a   Talmon, G ^b   Wisecarver, J L ^b   Are, C ^a   Brattain, M ^a   Wang, J ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Department of Pathology and Microbiology ^*  (United States)

Author keywords

Bcl 2; colon cancer; liver metastasis; miR 192; VEGFA; Zeb2

Indexed keywords

CADHERIN; HOMEODOMAIN PROTEIN; MICRORNA; MIRN192 MICRORNA, HUMAN; PROTEIN BCL 2; REPRESSOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; CELL SURVIVAL; COLON TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CADHERINS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027932009     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.478     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66. DOI: 10.3322/canjclin.57.1.43
2. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000; 21: 497–503. DOI: 10.1093/carcin/21.3.497
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458. DOI: 10.1038/nrc1098
4. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449–458. DOI: 10.1038/nrc1886
5. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180–184. DOI: 10.1038/36599
6. Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003; 10: 722–733. DOI: 10.1245/ASO.2003.07.019
7. Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev 2012; 31: 455–467. DOI: 10.1007/s10555-012-9379-3
8. Du T, Zamore PD. Microprimer: the biogenesis and function of microRNA. Development 2005; 132: 4645–4652. DOI: 10.1242/dev.02070
9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233. DOI: 10.1016/j.cell.2009.01.002
10. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20. DOI: 10.1016/j.cell.2004.12.035
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999–3004. DOI: 10.1073/pnas.0307323101
12. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1–12. DOI: 10.1016/j.ydbio.2006.08.028
13. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755–11760. DOI: 10.1073/pnas.0404432101
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857–866. DOI: 10.1038/nrc1997
15. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012; 11: 4352–4365. DOI: 10.4161/cc.22670
16. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS et al. MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One 2012; 7: e46743. DOI: 10.1371/journal.pone.0046743
17. Tian Q, Liang L, Ding J, Zha R, Shi H, Wang Q et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One 2012; 7: e48958. DOI: 10.1371/journal.pone.0048958
18. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 2005; 33: 6566–6578. DOI: 10.1093/nar/gki965
19. Simms N, Rajput A, Sharratt EA, Ongchin M, Teggart CA, Wang J et al. Transforming growth factor-ss suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer 2012; 12: 221. DOI: 10.1186/1471-2407-12-221
20. Jiang Y, Liu XQ, Rajput A, Geng L, Ongchin M, Zeng Q et al. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res 2011; 71: 234–244. DOI: 10.1158/0008-5472.CAN-10-1487
21. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11: 881–889. DOI: 10.1038/ncb1897
22. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425–436.
23. Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 2012; 3: 560–566. DOI: 10.3892/etm.2011.436
24. Liu XQ, Rajput A, Geng L, Ongchin M, Chaudhuri A, Wang J. Restoration of transforming growth factor-beta receptor II expression in colon cancer cells with microsatellite instability increases metastatic potential in vivo. J Biol Chem 2011; 286: 16082–16090. DOI: 10.1074/jbc.M111.221697
25. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell 2010; 17: 53–64. DOI: 10.1016/j.ccr.2009.11.021
26. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91–105. DOI: 10.1016/j.molcel.2007.06.017
27. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495–500. DOI: 10.1038/ng1536
28. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010; 11: R90. DOI: 10.1186/gb-2010-11-8-r90
29. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910–14914. DOI: 10.1074/jbc.C800074200
30. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894–907. DOI: 10.1101/gad.1640608
31. Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK et al. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996; 271: 17366–17371. DOI: 10.1074/jbc.271.29.17366
32. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S et al. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res 1999; 59: 4725–4731.
33. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995; 270: 22044–22049. DOI: 10.1074/jbc.270.37.22044
34. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336–1338. DOI: 10.1126/science.7761852
35. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008; 68: 4221–4228. DOI: 10.1158/0008-5472.CAN-07-5123
36. Zubeldia IG, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P144. Exp Cell Res 2013; 319: 12–22. DOI: 10.1016/j.yexcr.2012.11.004
37. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296–2302. DOI: 10.1158/0008-5472.CAN-04-3272
38. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23–35. DOI: 10.1016/j.ccr.2007.12.004
39. Kriegel AJ, Fang Y, Liu Y, Tian Z, Mladinov D, Matus IR et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 2010; 38: 8338–8347. DOI: 10.1093/nar/gkq718
40. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438–447. DOI: 10.1681/ASN.2009050530
41. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002; 51: 56–59. DOI: 10.1136/gut.51.1.56
42. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999; 59: 320–324.
43. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159–165. DOI: 10.1023/A:1008255511404
44. Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 2002; 22: 1769–1776.
45. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944–13949. DOI: 10.1073/pnas.0506654102
46. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 2008; 28: 3865–3870.
47. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998; 17: 227–236. DOI: 10.1038/sj.onc.1202019
48. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613. DOI: 10.1128/MCB.16.9.4604
49. Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep 2012; 27: 1200–1206. DOI: 10.3892/or.2011.1588
50. Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17: 7654–7663. DOI: 10.1158/1078-0432.CCR-10-2816
51. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875–883. DOI: 10.1084/jem.20110235
52. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010; 59: 1794–1802. DOI: 10.2337/db09-1736
53. Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 2011; 30: 1577–1585. DOI: 10.1038/onc.2010.534
54. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126–1132. DOI: 10.1158/1078-0432.CCR-08-0144
55. Moreira JN, Santos A, Simoes S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 2006; 1: 217–235. DOI: 10.2174/157488706778250050
56. Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 2010; 17: 2059–2065. DOI: 10.1245/s10434-010-0972-9
57. Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist 2012; 17: 1039–1050. DOI: 10.1634/theoncologist.2012-0068
58. Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res 1988; 48: 2469–2474.
59. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65: 3716–3725. DOI: 10.1158/0008-5472.CAN-04-3700